Document
type: Class

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

individual
rights: termsOfUse
date: 2026-08-24T03:47:03
publisher: Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
type: Document
label: RDF description of Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients - http://irises.unisr.it/resource/item/200747

Generically Dependent Continuant
type: Class

352413098
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

352413097
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
type: Entity
most specific type: Academic Article
type: Continuant
type: Thing
type: Article
type: Information Content Entity
type: Academic Article
type: Generically Dependent Continuant
related by: 352413098
related by: 352413097
language: Inglese
type: Document

Article
type: Class

Inglese
type: Language

Information Content Entity
type: Class